
AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand …

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

